InspireMD Inc
NASDAQ:NSPR

Watchlist Manager
InspireMD Inc Logo
InspireMD Inc
NASDAQ:NSPR
Watchlist
Price: 2.65 USD 2.71% Market Closed
Market Cap: 68.1m USD
Have any thoughts about
InspireMD Inc?
Write Note

InspireMD Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

InspireMD Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
InspireMD Inc
NASDAQ:NSPR
Revenue
$6.8m
CAGR 3-Years
28%
CAGR 5-Years
14%
CAGR 10-Years
7%
N
Nissan Medical Industries Ltd
TASE:NISA
Revenue
â‚Ş729m
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
A
Allmed Solutions Ltd
TASE:ALMD
Revenue
â‚Ş0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

InspireMD Inc
Revenue Breakdown

Breakdown by Geography
InspireMD Inc

Total Revenue: 6.2m USD
100%
Other Countries: 3.4m USD
54.4%
Italy: 1.2m USD
19.3%
Germany: 896k USD
14.4%
Russian Federation: 738k USD
11.9%
Show More
Show Less

Breakdown by Segments
InspireMD Inc

Total Revenue: 6.2m USD
100%
C Guard E P S: 6.2m USD
100%

InspireMD Inc
Glance View

Market Cap
68.2m USD
Industry
Health Care

InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

NSPR Intrinsic Value
2.62 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is InspireMD Inc's Revenue?
Revenue
6.8m USD

Based on the financial report for Sep 30, 2024, InspireMD Inc's Revenue amounts to 6.8m USD.

What is InspireMD Inc's Revenue growth rate?
Revenue CAGR 10Y
7%

Over the last year, the Revenue growth was 25%. The average annual Revenue growth rates for InspireMD Inc have been 28% over the past three years , 14% over the past five years , and 7% over the past ten years .

Back to Top